{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:57:36Z","timestamp":1785473856850,"version":"3.56.0"},"reference-count":42,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Tildrakizumab is a humanized IgG1\u03ba monoclonal antibody that selectively targets the p19 subunit of interleukin IL-23, thereby inhibiting the IL-23\/IL-17 axis, which is primarily implicated in the immunopathogenesis of psoriasis. Tildrakizumab is approved for the treatment of moderate-to-severe plaque-type psoriasis in adults based on the evidence of two randomized and controlled phase-III clinical trials (reSURFACE 1 and reSURFACE 2). Here, we report our real-life experience treating 53 psoriatic patients (19 female and 34 male) who were administered tildrakizumab every 12 weeks and received follow-ups over 52 weeks. Descriptive and inferential statistical analyses were performed, in particular the Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI) and, if applicable, the Nail Psoriasis Severity Index (NAPSI) and Palmoplantar Psoriasis Physician Global Assessment (PPPGA). These were assessed at baseline and after different timepoints (weeks) during the follow-up period. We described and evaluated demographical and epidemiological characteristics in our cohort group, focusing on comorbidities. In this group, 35.9% of patients were female and 64.1% were male, with 47.1% being smokers and with a mean age of 51.2 years. A total of 37.7% of these patients was affected by scalp psoriasis; regarding comorbidities, hypertension was the most frequent (32.5%), followed by psoriatic arthritis (PsA) (18.60%) and diabetes (13.9%). At week 52, 93%, 90.2% and 77% of patients achieved a PASI reduction \u226575% (PASI 75), PASI 90 and PASI 100, respectively. In addition, NAPSI, PPPGA and DLQI scores were significantly reduced by week 52. In our cohort of complex psoriasis patients, disease remission began at the end of the fourth week of treatment and remained constant from week 16 to week 52.<\/jats:p>","DOI":"10.3390\/ph16040526","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T09:12:59Z","timestamp":1680253979000},"page":"526","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients"],"prefix":"10.3390","volume":"16","author":[{"given":"Elena","family":"Campione","sequence":"first","affiliation":[{"name":"Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lambiase","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruslana","family":"Gaeta Shumak","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Galluzzo","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Lanna","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1115-4270","authenticated-orcid":false,"given":"Gaetana","family":"Costanza","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Borselli","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Artosi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4025-7882","authenticated-orcid":false,"given":"Terenzio","family":"Cosio","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"},{"name":"Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Tofani","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annunziata","family":"Dattola","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Di Daniele","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8697-6896","authenticated-orcid":false,"given":"Luca","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"13554","DOI":"10.1111\/jcmm.15742","article-title":"Overview of the molecular determinants contributing to the expression of Psoriasis and Psoriatic Arthritis phenotypes","volume":"24","author":"Caputo","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e15818","DOI":"10.1111\/dth.15818","article-title":"Tildrakizumab in real-life shows good efficacy in moderate-to-severe psoriasis regardless of previous use of biologic drugs and joint involvement","volume":"35","author":"Mastorino","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1080\/15384101.2019.1653099","article-title":"Skin immunity and its dysregulation in psoriasis","volume":"18","author":"Lanna","year":"2019","journal-title":"Cell Cycle"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1080\/09546634.2020.1826394","article-title":"Comparison of psoriasis guidelines for use of IL-23 inhibitors in the United States and United Kingdom: A critical appraisal and comprehensive review","volume":"33","author":"Ghamrawi","year":"2020","journal-title":"J. Dermatol. Treat."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities","volume":"80","author":"Elmets","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1080\/00015550260132488","article-title":"Palmoplantar lesions in psoriasis: A study of 3065 patients","volume":"82","author":"Kumar","year":"2002","journal-title":"Acta Derm. Venereol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/archdermatol.2010.168","article-title":"Increased IL-23 expression in palmoplantar psoriasis and hyperkeratotic hand dermatitis","volume":"146","author":"Lillis","year":"2010","journal-title":"Arch. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"111994","DOI":"10.1016\/j.celrep.2023.111994","article-title":"Differential cell composition and split epidermal differentiation in human palm, sole, and hip skin","volume":"42","author":"Wiedemann","year":"2023","journal-title":"Cell Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jaad.2020.09.047","article-title":"Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)","volume":"84","author":"Lebwohl","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1080\/14712598.2022.2089020","article-title":"Treating psoriasis in the elderly: Biologics and small molecules","volume":"22","author":"Megna","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_12","first-page":"2021-2-6","article-title":"Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting","volume":"10","author":"Burlando","year":"2021","journal-title":"Drugs Context"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/bjd.18232","article-title":"Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: Pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks","volume":"182","author":"Reich","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/bjd.19866","article-title":"Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: Pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)","volume":"185","author":"Thaci","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/14712598.2022.1988566","article-title":"Tildrakizumab for treatment of moderate to severe psoriasis: An expert opinion of efficacy, safety, and use in special populations","volume":"22","author":"Galluzzo","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris-Part 1: Treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e15793","DOI":"10.1111\/dth.15793","article-title":"Successful use of anti-IL-23 molecules in overweight-to-obese psoriatic patients: A multicentric retrospective study","volume":"35","author":"Ricceri","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"a028530","DOI":"10.1101\/cshperspect.a028530","article-title":"Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer. Review","volume":"10","author":"Yan","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Prignano, F., Brunasso, A.M.G., Fabbrocini, G., Argenziano, G., Bardazzi, F., Borroni, R.G., Burlando, M., Cagni, A.E., Campione, E., and Cinotti, E. (2022). Sharing Patient and Clinician Experiences of Moderate-to-Severe Psoriasis: A Nationwide Italian Survey and Expert Opinion to Explore Barriers Impacting upon Patient Wellbeing. J. Clin. Med., 11.","DOI":"10.3390\/jcm11102801"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e14584","DOI":"10.1111\/dth.14584","article-title":"Effectiveness of anti-interleukin 23 biologic drugs in psoriasis patients who failed anti-interleukin 17 regimens. A real-life experience","volume":"34","author":"Bonifati","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1159\/000519924","article-title":"Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients","volume":"238","author":"Drerup","year":"2022","journal-title":"Dermatology"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Galluzzo, M., Talamonti, M., Cioni, A., Maffei, V., Shumak, R.G., Tofani, L., Bianchi, L., and Campione, E. (2022). Efficacy of Tildrakizumab for the treatment of Difficult-to-Treat areas: Scalp, Nail, Palmoplantar and Genital Psoriasis. J. Clin. Med., 11.","DOI":"10.3390\/jcm11092631"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1080\/09546634.2022.2081655","article-title":"Real-world practice indirect comparison between guselkumab, risankizumab and tildrakizumab: Results from an Italian 28-week retrospective study","volume":"33","author":"Megna","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e15030","DOI":"10.1111\/dth.15030","article-title":"Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?","volume":"34","author":"Megna","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/jdv.18594","article-title":"Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis)","volume":"37","author":"Narcisi","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9447","DOI":"10.4081\/dr.2022.9447","article-title":"Long term efficacy, safety, and tolerability of tildrakizumab in epileptic patient with psoriasis and eczema","volume":"14","author":"Bernardini","year":"2022","journal-title":"Dermatol. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/jdv.18572","article-title":"Real-world effectiveness and safety of tildrakizumab in long-term treatment of plaque psoriasis: Results from the non-interventional, prospective, multicentre study TILOT","volume":"37","author":"Tsianakas","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"eabq3254","DOI":"10.1126\/sciimmunol.abq3254","article-title":"Local IL-23 is required for proliferation and retention of skin-resident memory TH17 cells","volume":"7","author":"Whitley","year":"2022","journal-title":"Sci. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"703","DOI":"10.36849\/JDD.2020.5337","article-title":"The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2)","volume":"19","author":"Menter","year":"2020","journal-title":"J. Drugs Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e060536","DOI":"10.1136\/bmjopen-2021-060536","article-title":"Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: Protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study)","volume":"13","author":"Augustin","year":"2023","journal-title":"BMJ Open"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1080\/09546634.2020.1832187","article-title":"Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: Pooled analysis of 4 phase 3 clinical trials","volume":"33","author":"Gottlieb","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1590\/abd1806-4841.20165080","article-title":"Psoriasis comorbidities: Complications and benefits of immunobiological treatment","volume":"91","author":"Alegre","year":"2016","journal-title":"An. Bras. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1517\/14712598.2012.646986","article-title":"Anti-TNF drugs in patients with hepatitis B or C virus infection: Safety and clinical management","volume":"12","author":"Degasperi","year":"2012","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","article-title":"Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: A systematic review and meta-analysis","volume":"15","author":"Minozzi","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jphs.2020.06.003","article-title":"Predictive role of vitamin A serum concentration in psoriatic patients treated with IL-17 inhibitors to prevent skin and systemic fungal infections","volume":"144","author":"Campione","year":"2020","journal-title":"J. Pharmacol. Sci."},{"key":"ref_36","first-page":"316","article-title":"Biomolecular index of therapeutic efficacy in psoriasis treated with anti-TNF-\u03b1 agents","volume":"153","author":"Bianchi","year":"2018","journal-title":"G. Ital. Dermatol. Venereol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.2147\/DDDT.S136986","article-title":"New insight into the pathogenesis of nail psoriasis and overview of treatment strategies","volume":"11","author":"Ventura","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40257-019-00435-9","article-title":"Tildrakizumab: A Review in Moderate-to-Severe Plaque Psoriasis","volume":"20","author":"Frampton","year":"2019","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2217\/imt-2018-0028","article-title":"Tildrakizumab for the treatment of psoriasis","volume":"10","author":"Bangert","year":"2018","journal-title":"Immunotherapy"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/ced.14979","article-title":"Anti-interleukin-23 for psoriasis in elderly patients: Guselkumab, risankizumab and tildrakizumab in real-world practice","volume":"47","author":"Ruggiero","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/jdv.15653","article-title":"Safety of selective IL-23p19 inhibitors for the treatment of psoriasis","volume":"33","author":"Crowley","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"36736","DOI":"10.18632\/oncotarget.26314","article-title":"Expression and potential role of cellular retinol binding protein I in psoriasis","volume":"9","author":"Costanza","year":"2018","journal-title":"Oncotarget"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/4\/526\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:07:41Z","timestamp":1760123261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/4\/526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,31]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["ph16040526"],"URL":"https:\/\/doi.org\/10.3390\/ph16040526","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,31]]}}}